E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
multiple myeloma |
Myelomatose |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028228 |
E.1.2 | Term | Multiple myeloma |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of the study is to investigate if treatment with ixazomib can cause healing of preexisting osteolytic bone lesions in Multiple Myeloma. |
|
E.2.2 | Secondary objectives of the trial |
Increased bone formation during Ixazomib treatment in NaF PET. Increased bone anabolism during Ixazomib treatment. Increased bone formation to bone degradation ratio during Ixazomib treatment. Increased bone formation using bone histomorphometric evaluation. Investigate safety and toxicities during Ixazomib treatment. Depth of cancer response to Ixazomib treatment. Adherence to therapy. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Symptomatic Multiple Myeloma according to the IMWG criteria.
• Detectable osteolysis on low dose CT (at least 5 mm in size).
• Stable disease, defined as no signs of progressive disease for three months without anti myeloma treatment (appendix 1).
• Achieved, partial response or better, during last line of therapy.
• Signed informed consent.
• Age ≥ 18 years.
• Remaining life expectancy ≥ 6 months.
• ECOG performance status 0-2 (see appendix 2).
Female patients who:
• Are postmenopausal for at least 1 year before the screening visit, OR • Are surgically sterile, OR • If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.)
Male patients, even if surgically sterilized (ie, status post-vasectomy), must agree to one of the following:
• Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR • Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception.) |
|
E.4 | Principal exclusion criteria |
• Treatment with denosumab within the last 4 weeks.
• Known concurrent malignancy (last five years), excluding skin cancer.
• Known hypersensitivity to Ixazomib.
• Central nervous system involvement.
• Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
• Pregnant or lactating women.
• Absolute neutrophil count <1,000/mm3 without growth factor support.
• Platelet count <75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before inclusion -Total bilirubin >1.5 x the upper limit of the normal range.
• Alanine aminotransferase >3 x upper limit of the normal range.
• Calculated creatinine clearance < 30 mL/min (using the Cockcroft-Gault equation).
• Total bilirubin > 1.5 x the upper limit of the normal range (ULN).
• Radiotherapy within 14 days before inclusion.
• Major surgery within 14 days before inclusion.
• Evidence of current uncontrolled cardiovascular conditions, including uncontrolledhypertension, uncontrolled cardiac arrhythmias, uncontrolled congestive heart failure,unstable angina, or myocardial infarction within the past 6 months.
• Systemic treatment with strong CYP3A inducers (rifampin, rifapentine, rifabutin,carbamazepine, phenytoin, phenobarbital) or use of St. John’s wort.
• Peripheral neuropathy grade 1 with pain or grade 2.
• Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
• Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of Ixazomibzomib including difficulty swallowing.
• Infection requiring systemic antibiotic therapy or other serious infection within 14 days before study enrollment.
• Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Healing of preexisting osteolytic bone lesions in Multiple Myeloma. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after 3 months and 2 years of therapy |
|
E.5.2 | Secondary end point(s) |
Increased bone formation during Ixazomib treatment in NaF PET. Increased bone anabolism during Ixazomib treatment. Increased bone formation to bone degradation ratio during Ixazomib treatment. Increased bone formation using bone histomorphometric evaluation. Investigate safety and toxicities during Ixazomib treatment. Depth of cancer response to Ixazomib treatment. Adherence to therapy. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
secondary endpoints will be evaluated continuously during the trial |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
30 patients will be included in the trial All patients will be treated for 24 months The trial will end when the last patient has received the last treatment An additional follow up of three months is planned |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |